Shares of Celgene Has Risen Above Previous 52-Week High
Shares of Celgene (NASDAQ:CELG) traded today at $139.90, breaking its 52-week high. So far today approximately 824,000 shares have been exchanged, as compared to an average 30-day volume of 2.7 million shares.
There is potential upside of 2.8% for shares of Celgene based on a current price of $137.43 and an average consensus analyst price target of $141.28. The stock should discover initial support at its 50-day moving average (MA) of $123.46 and subsequent support at its 200-day MA of $102.97.
Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
In the past 52 weeks, shares of Celgene have traded between a low of $63.89 and a high of $139.90 and are now at $137.43, which is 115% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.9% while the 50-day MA has advanced 0.5%.
SmarTrend recommended that subscribers consider buying shares of Celgene on July 5th, 2013 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $121.88. Since that recommendation, shares of Celgene have risen 11.6%. We continue to monitor CELG for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Keywords: 52 week high/lows Celgene